Physician profile
Rameet Thapa
NPI 1346553534
$2,597.99
in general payments reported to CMS, 2019-2025
20 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $81.46 · 2021: $342 · 2022: $302 · 2023: $568 · 2024: $511 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $747.92 | 2021-2025 | Avycaz, Teflaro, Dalvance |
| Astrazeneca Pharmaceuticals LP | $414.02 | 2024-2025 | Tezspire, Fasenra |
| Insmed, INC. | $258.66 | 2021-2025 | Arikayce |
| Allergan, INC. | $203.26 | 2019-2020 | |
| Grifols USA, LLC | $161.25 | 2023 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $158.72 | 2019-2020 | |
| Angiodynamics, INC. | $143.72 | 2025 | Angiovac |
| Verona Pharma, INC. | $121.91 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.15 | 2023 | Lifevest |
| Glaxosmithkline, LLC. | $78.36 | 2023 | Arexvy |
| Accelerate Diagnostics INC. | $39.69 | 2022 | |
| Melinta Therapeutics, LLC | $39.01 | 2019 | |
| Hartmann USA, INC. | $21.79 | 2021 | |
| Pfizer INC. | $19.53 | 2021 | |
| Gilead Sciences, INC. | $17.79 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $15.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.71 | 2023 | Xarelto |
| Philips North America LLC | $13.28 | 2020 | |
| Dynavax Technologies Corporation | $11.80 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rameet Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.